Drug recall · May 20, 2020
Memantine Hydrochloride Extended-Release Capsules recall
Why: Failed dissolution specifications: Low stage 3 results obtained for dissolution during routine stability testing.
Class III: unlikely to cause harm, but breaks the rules (for example a labeling error).
The recall
- Product
Memantine Hydrochloride Extended-Release Capsules, 28 mg, 100 capsules per unit dose cartons, Rx only, Manufactured by: Lupin Limited, Pithampur (M.P.)-454 775, India; Distributed by: Major Pharmaceuticals, 17177 N Laurel Park Dr., Suite 233, Livonia, MI 47152 USA. NDC: 0904-6735-61
- Lots / codes
Lot #: M02199D, M02246D, Exp 5/2020
- Quantity
- 678 cartons
- Company
- The Harvard Drug Group, Livonia, MI
- Distribution
- AL, FL, IA, NY, OH, TX
- Initiated
- April 24, 2020 · Voluntary: Firm initiated
- Classified
- May 13, 2020
- Reported
- May 20, 2020
- Ended
- August 19, 2022
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Memantine
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.